Locteron is form of interferon currently being tested that uses controlled release. Locteron lasts longer in the body than pegylated interferon therefore injections are reduced from once a week to once every two weeks.
According to 3 studies presented at the annual meeting of the European Association for the Study of the Liver (EASL 2010), patients achieved undetectable HCV viral loads similar to that of patients taking regular pegylated interferon. However, those taking Locteron reported fewer flu-like symptoms.
Consensus interferon is a genetically engineered synthetic interferon. Several clinical studies suggest that it has greater antiviral activity in people infected with genotype 1, particularly if given as a daily injection. Interfergen is a type of consensus interferon which has now been approved in the US for HCV treatment in people with compensated cirrhosis.
Recent studies have also shown that when used in combination with Ribavirin, Consensus interferon (infergen) offers a very optimistic option for HEP C Genotype 3 relapsers with Peg Interferon Ribavirin combination.
Omega Interferon is a new formulation of interferon designed to specifically target the liver, thus reducing side effects elsewhere in the body. It uses an implantable infusion pump that releases a steady amount of Omega for 90 days.
A Phase II trial, evaluating daily omega interferon alone and in combination with ribavirin, in 102 HCV first-time patients with genotype 1 has now finished. The final results from the study reported at EASL 2007 found that 36% of patients who received daily Omega interferon plus ribavirin achieved SVR, compared to 6% who received Omega interferon monotherapy. The company is currently recruiting patients for a Phase Ib trial in genotype 1 patients who have relapsed after prior interferon/ribavirin treatment.
A type of natural interferon that has been approved to treat HCV in various countries outside of the United States. No new clinical trials of multiferon have been announced in the U.S.
PEG-Interferon lambda (IL-29)
On January 12, 2009, Bristol-Myers announced that it signed an agreement with ZymoGenetics to co-develop IL-29. On October 27, 2010, ZymoGenetics announced they had dosed the first patient in a Phase 2 clinical trial of PEG-Interferon lambda (IL-29) and ribavirin in treatment-naïve patients with chronic hepatitis C virus (HCV) infection.
PEG-Interferon lambda is a member of the Type III lambda interferon family. Type III interferons signal through a different receptor than type I interferons, such as interferon alpha.